With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1029413-55-5,tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate,as a common compound, the synthetic route is as follows.
[0554j A mixture of 2-chloro-4-methoxypyrimidine (970 mg, 6.7 mmol), tert-butyl 4-(4- amino-1H-pyrazol-1-yl)piperidine-1-carboxylate (1.8 g, 6.77 mmol), S-phos (548 mg, 1.35 mmol), Pd2(dba)3 (577 mg, 0.63 mmol) and NaOtBu (1.9 g, 20.2 mmol) in 1,4-dioxane (18 mL) was stirred at 115 C for 2 h under nitrogen. After dilution with EtOAc (200 mL), the mixture was washed with water and brine. The organic phase was concentrated and the residue was purified by silica gel colunm (petroleum ether: EtOAc , 4:1 to 2:1) to give the compound ten?butyl 4-(4-((4-methoxypyrimidin-2-yl)amino)- 1H-pyrazol- 1 -yl)piperidine- 1 -carboxylate (1.15 g, yield: 48%) as a gray solid. ESI-MS (M+H): 375.2.
1029413-55-5, As the paragraph descriping shows that 1029413-55-5 is playing an increasingly important role.
Reference£º
Patent; BIOGEN IDEC MA INC.; SUNESIS PHARMACEUTICALS, INC.; HOPKINS, Brian, T.; MA, Bin; CHAN, Timothy, Raymond; SUN, Lihong; ZHANG, Lei; KUMARAVEL, Gnanasambandam; LYSSIKATOS, Joseph, P.; KOCH, Kevin; MIAO, Hua; WO2015/89337; (2015); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem